LONDON (Alliance News) - Vectura Group PLC Wednesday said a milestone payment of USD3.8 million has been triggered as a result of the first patients being enrolled in Novartis AG's phase III trial of QVM149 for moderate to severe asthma.
The treatment was licensed to Novartis in April 2005 by Vectura and its co-development partner Sosei Co Ltd.
Vecutre said that first regulatory filings of QVM149 are planned for 2018.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
